Cryptocurrency & Digital Assets

FDA clears a novel two-part immunotherapy that paints solid tumors with a synthetic target, unleashing a powerful CAR T-cell attack in a new clinical trial.

Promising new 96-week data shows Vir's therapy could redefine care for severe hepatitis delta, as its oncology pipeline and financial runway also advance.

The insurance giant landed a major credit facility, calming investor nerves and doubling down on its fast-growing pharmacy and healthcare services arm.

With preliminary Q1 revenue of $103.7M, Twist Bioscience beats forecasts, setting a bullish tone ahead of its full earnings report on February 2nd.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

With a major strategic pivot complete, Gibraltar Industries' leadership will outline its 2026 playbook to investors at a key 'New Ideas' conference.

Interim data suggests LX2020 is well-tolerated and may reduce dangerous arrhythmias by targeting the root cause of PKP2-associated cardiomyopathy.

Backed by Purolator, a massive network expansion by Williams Pharmalogistics aims to reshape Canada's temperature-controlled medical delivery landscape.

As the ISS era ends, Mitsubishi Corporation's major investment in Starlab Space secures Japan's future in orbit and heats up the commercial space race.

Adaptive posted a 55% revenue surge in 2025, fueled by its clonoSEQ cancer test. Now, the firm is charting a clear course to company-wide profitability.

A new clinical trial for AB001, a potent alpha radioligand therapy, offers hope for patients with advanced prostate cancer, including those resistant to current treatments.

With FDA alignment for its rapid postpartum depression therapy and new trials for anxiety, Reunion Neuroscience is pioneering a new era of mental health.

KEY Investment Partners acquires BellRock Brands' portfolio out of receivership, launching MM Brands with Joe Bayern to lead a wellness-focused revival.

With pivotal cancer drug data looming and a new nuclear supply chain, Bicycle Therapeutics is betting big on its novel platform. Will 2026 be its breakout year?

The firm gives bondholders more time to trade near-term notes for a higher yield, sparking debate on strategy versus necessity in a tough market.

Uniper secures 500,000 tons of certified green ammonia from India's AM Green, forging a new energy axis and fueling Europe's industrial decarbonization.

CoinEx's consistent token burning removes over 166M CET in a year, signaling a long-term commitment to scarcity and value in a competitive market.

Dolf van den Brink will step down in 2026 after a turbulent tenure, leaving an ambitious new strategy for his successor to execute amid market skepticism.

With fresh capital and full regulatory approval, InsurTech carrier Corgi is using AI to overhaul the slow, rigid world of startup insurance.

Recent findings of bacteria and heavy metals in baby formula have parents worried and legal experts demanding greater manufacturer accountability.